Oded Shamriz1, Bella Shadur2,3,4, Adeeb NaserEddin2, Irina Zaidman2, Natalia Simanovsky5, Orly Elpeleg6, Eitan Kerem7, Joel Reiter7, Polina Stepensky2. 1. Pediatric Division, Hadassah-Hebrew University Medical Center, POB 12000, Kiryat Hadassah, 91120, Jerusalem, Israel. oded.shamriz@mail.huji.ac.il. 2. Bone Marrow Transplantation Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 3. Garvan Institute of Medical Research, Sydney, Australia. 4. University of New South Wales, Sydney, Australia. 5. Department of Radiology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 6. Monique and Jacques Roboh Department of Genetic Research, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 7. Department of Pediatrics and Pediatric Pulmonology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Abstract
Lipopolysaccharide (LPS)-responsive beige-like anchor (LRBA) protein deficiency is a rare syndrome of primary immune deficiency and immune dysregulation. In this study, we sought to summarize our experience with respiratory manifestations in LRBA-deficient patients. We conducted a retrospective analysis of the medical records of LRBA-deficient patients treated at Hadassah-Hebrew University Medical Center, Jerusalem, Israel. Data retrieved included pulmonary workup, disease course, treatment, and outcome. Ten patients were included. Mean age at presentation of LRBA deficiency-related symptoms was 4.65 years (range 3 months-14 years). Respiratory symptoms were noted in six patients and consisted of chronic cough. Computed tomography revealed consolidation in five patients, atelectasis and bronchiectasis in two patients each, and diffuse interstitial lung disease in two additional patients. Respiratory tract cultures yielded a bacterial pathogen in five patients. Seven patients required active therapy: intravenous immunoglobulins (six patients), immunosuppressive drugs (five patients), and one was successfully treated with abatacept. Two patients underwent successful bone marrow transplantation. Mean follow-up period was 4.5 (range 0.4-14.4) years. On their latest examination, seven patients had no respiratory symptoms. CONCLUSION: Pulmonary manifestations are common in LRBA deficiency. Respiratory characteristics in LRBA-deficient patients should be investigated, monitored, and treated from the time of diagnosis. What is Known: • Lipopolysaccharide-responsive beige-like anchor (LRBA) deficiency is a syndrome of primary immune deficiency and immune dysregulation. • Studies concerning the pulmonary characteristics of LRBA-deficient patients are lacking. What is New: • Respiratory manifestations include infections, bronchiectasis, interstitial lung disease, thoracic lymphadenopathy, and clubbing. • Awareness to pulmonary morbidity in LRBA-deficient patients and involvement of a pulmonologist in the workup and clinical decision-making is important. • Respiratory characteristics in LRBA-deficient patients should be investigated, monitored, and treated from a young age.
Lipopolysaccharide (LPS)-responsive beige-like anchor (LRBA) protein deficiency is a rare syndrome of primary immune deficiency and immune dysregulation. In this study, we sought to summarize our experience with respiratory manifestations in LRBA-deficientpatients. We conducted a retrospective analysis of the medical records of LRBA-deficientpatients treated at Hadassah-Hebrew University Medical Center, Jerusalem, Israel. Data retrieved included pulmonary workup, disease course, treatment, and outcome. Ten patients were included. Mean age at presentation of LRBA deficiency-related symptoms was 4.65 years (range 3 months-14 years). Respiratory symptoms were noted in six patients and consisted of chronic cough. Computed tomography revealed consolidation in five patients, atelectasis and bronchiectasis in two patients each, and diffuse interstitial lung disease in two additional patients. Respiratory tract cultures yielded a bacterial pathogen in five patients. Seven patients required active therapy: intravenous immunoglobulins (six patients), immunosuppressive drugs (five patients), and one was successfully treated with abatacept. Two patients underwent successful bone marrow transplantation. Mean follow-up period was 4.5 (range 0.4-14.4) years. On their latest examination, seven patients had no respiratory symptoms. CONCLUSION: Pulmonary manifestations are common in LRBA deficiency. Respiratory characteristics in LRBA-deficientpatients should be investigated, monitored, and treated from the time of diagnosis. What is Known: • Lipopolysaccharide-responsive beige-like anchor (LRBA) deficiency is a syndrome of primary immune deficiency and immune dysregulation. • Studies concerning the pulmonary characteristics of LRBA-deficientpatients are lacking. What is New: • Respiratory manifestations include infections, bronchiectasis, interstitial lung disease, thoracic lymphadenopathy, and clubbing. • Awareness to pulmonary morbidity in LRBA-deficientpatients and involvement of a pulmonologist in the workup and clinical decision-making is important. • Respiratory characteristics in LRBA-deficientpatients should be investigated, monitored, and treated from a young age.
Authors: Bernice Lo; Kejian Zhang; Wei Lu; Lixin Zheng; Qian Zhang; Chrysi Kanellopoulou; Yu Zhang; Zhiduo Liu; Jill M Fritz; Rebecca Marsh; Ammar Husami; Diane Kissell; Shannon Nortman; Vijaya Chaturvedi; Hilary Haines; Lisa R Young; Jun Mo; Alexandra H Filipovich; Jack J Bleesing; Peter Mustillo; Michael Stephens; Cesar M Rueda; Claire A Chougnet; Kasper Hoebe; Joshua McElwee; Jason D Hughes; Elif Karakoc-Aydiner; Helen F Matthews; Susan Price; Helen C Su; V Koneti Rao; Michael J Lenardo; Michael B Jordan Journal: Science Date: 2015-07-24 Impact factor: 47.728
Authors: Laura Gámez-Díaz; Dietrich August; Polina Stepensky; Shoshana Revel-Vilk; Markus G Seidel; Mitsuiki Noriko; Tomohiro Morio; Austen J J Worth; Jacob Blessing; Frank Van de Veerdonk; Tobias Feuchtinger; Maria Kanariou; Annette Schmitt-Graeff; Sophie Jung; Suranjith Seneviratne; Siobhan Burns; Bernd H Belohradsky; Nima Rezaei; Shahrzad Bakhtiar; Carsten Speckmann; Michael Jordan; Bodo Grimbacher Journal: J Allergy Clin Immunol Date: 2016-01 Impact factor: 10.793
Authors: Desirée Schubert; Claudia Bode; Rupert Kenefeck; Tie Zheng Hou; Lucy S K Walker; David M Sansom; Bodo Grimbacher; James B Wing; Alan Kennedy; Alla Bulashevska; Britt-Sabina Petersen; Alejandro A Schäffer; Björn A Grüning; Susanne Unger; Natalie Frede; Ulrich Baumann; Torsten Witte; Reinhold E Schmidt; Gregor Dueckers; Tim Niehues; Suranjith Seneviratne; Maria Kanariou; Carsten Speckmann; Stephan Ehl; Anne Rensing-Ehl; Klaus Warnatz; Mirzokhid Rakhmanov; Robert Thimme; Peter Hasselblatt; Florian Emmerich; Toni Cathomen; Rolf Backofen; Paul Fisch; Maximilian Seidl; Annette May; Annette Schmitt-Graeff; Shinji Ikemizu; Ulrich Salzer; Andre Franke; Shimon Sakaguchi Journal: Nat Med Date: 2014-10-20 Impact factor: 53.440
Authors: Deborah L Burnett; Ian A Parish; Etienne Masle-Farquhar; Robert Brink; Christopher C Goodnow Journal: Immunol Cell Biol Date: 2017-06-14 Impact factor: 5.126
Authors: Tie Zheng Hou; Nisha Verma; Jennifer Wanders; Alan Kennedy; Blagoje Soskic; Daniel Janman; Neil Halliday; Behzad Rowshanravan; Austen Worth; Waseem Qasim; Helen Baxendale; Hans Stauss; Suranjith Seneviratne; Olaf Neth; Peter Olbrich; Sophie Hambleton; Peter D Arkwright; Siobhan O Burns; Lucy S K Walker; David M Sansom Journal: Blood Date: 2017-02-03 Impact factor: 22.113